Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MLAB | Mesa Laboratories, Inc.

IndexRUT P/E333.16 EPS (ttm)0.34 Insider Own3.50% Shs Outstand5.37M Perf Week-8.11%
Market Cap621.17M Forward P/E83.97 EPS next Y1.34 Insider Trans-6.61% Shs Float5.07M Perf Month-18.72%
Income1.80M PEG- EPS next Q0.15 Inst Own92.50% Short Float / Ratio7.15% / 10.70 Perf Quarter-11.14%
Sales219.30M P/S2.83 EPS this Y-50.50% Inst Trans-1.47% Short Interest0.36M Perf Half Y-33.36%
Book/sh72.17 P/B1.56 EPS next Y97.79% ROA0.30% Target Price152.50 Perf Year-22.40%
Cash/sh5.89 P/C19.17 EPS next 5Y- ROE0.50% 52W Range111.48 - 206.36 Perf YTD-32.05%
Dividend0.64 P/FCF17.21 EPS past 5Y17.30% ROI0.80% 52W High-45.27% Beta0.77
Dividend %0.57% Quick Ratio2.00 Sales past 5Y17.90% Gross Margin60.90% 52W Low1.31% ATR4.72
Employees698 Current Ratio2.90 Sales Q/Q0.20% Oper. Margin3.30% RSI (14)27.56 Volatility3.51% 3.68%
OptionableNo Debt/Eq0.45 EPS Q/Q62.50% Profit Margin0.80% Rel Volume1.24 Prev Close113.00
ShortableYes LT Debt/Eq0.45 EarningsAug 03 BMO Payout187.20% Avg Volume33.86K Price112.94
Recom2.30 SMA20-12.79% SMA50-13.77% SMA200-27.55% Volume41,919 Change-0.05%
Date Action Analyst Rating Change Price Target Change
Jan-04-21Downgrade Evercore ISI Outperform → In-line $300
Nov-10-20Initiated KeyBanc Capital Markets Sector Weight $287
Oct-02-20Initiated JP Morgan Neutral $260
Dec-04-19Initiated Jefferies Buy
Aug-26-19Initiated Evercore ISI Outperform $250
Jun-10-16Downgrade Sidoti Buy → Neutral
Sep-22-23 08:09AM
Sep-15-23 01:10AM
Sep-13-23 01:37PM
Sep-11-23 11:21AM
04:02PM Loading…
Aug-24-23 04:02PM
Aug-10-23 01:32AM
Aug-03-23 09:35AM
Jul-31-23 07:50AM
Jul-05-23 03:00PM
Jun-21-23 08:00PM
May-25-23 09:25AM
08:14AM Loading…
May-22-23 01:16PM
May-02-23 06:23AM
Apr-26-23 08:00PM
Apr-03-23 06:15PM
Mar-13-23 08:00AM
Mar-09-23 08:00AM
Feb-21-23 05:36AM
Feb-14-23 09:00AM
Feb-13-23 12:45PM
Feb-06-23 09:55AM
08:36AM Loading…
Feb-01-23 12:43PM
Jan-27-23 06:00PM
Jan-19-23 06:15PM
Jan-17-23 04:33PM
Jan-13-23 06:00PM
Jan-12-23 09:40AM
Jan-11-23 06:26AM
Jan-09-23 06:15PM
Jan-03-23 05:00PM
Dec-28-22 06:51AM
Dec-18-22 04:48PM
Dec-16-22 11:59AM
Nov-23-22 12:20PM
Nov-17-22 08:04AM
Nov-08-22 06:48AM
Nov-04-22 03:49PM
Nov-03-22 10:25AM
Oct-25-22 06:32AM
Oct-03-22 02:00PM
Sep-11-22 08:33AM
Aug-04-22 11:05AM
Jul-28-22 10:03AM
Jul-06-22 07:00PM
Jun-27-22 08:01AM
May-31-22 09:25AM
May-13-22 10:17AM
Apr-12-22 09:51AM
Apr-06-22 01:10PM
Apr-04-22 12:02PM
Feb-03-22 09:25AM
Jan-26-22 03:01PM
Jan-06-22 03:00PM
Dec-21-21 08:01AM
Dec-20-21 12:48PM
Dec-16-21 10:47AM
Dec-11-21 09:15AM
Nov-04-21 10:55AM
Oct-29-21 08:00AM
Oct-28-21 03:05PM
Oct-21-21 09:35AM
Oct-20-21 12:05PM
Oct-08-21 05:48AM
Oct-01-21 03:00PM
Sep-14-21 01:02PM
Sep-13-21 11:49AM
Aug-22-21 10:38AM
Aug-05-21 11:15AM
Jul-29-21 03:05PM
Jul-08-21 04:54AM
Jul-06-21 07:19PM
Jun-01-21 08:00AM
May-31-21 03:00PM
May-24-21 04:40AM
Apr-19-21 12:42PM
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schmieder John BradleyDirectorSep 15Sale123.741,000123,74062,760Sep 19 12:34 PM
Schmieder John BradleyDirectorSep 14Sale123.053,000369,15063,760Sep 19 12:34 PM
Schmieder John BradleyDirectorSep 13Sale123.323,000369,96566,760Sep 14 01:47 PM
Owens Gary MPresident and CEOSep 01Option Exercise136.422,000272,84032,032Sep 05 04:34 PM
Owens Gary MPresident and CEOSep 01Sale142.822,000285,64030,032Sep 05 04:34 PM
Tripeny R TonyDirectorAug 15Option Exercise0.001,10501,605Aug 16 03:54 PM
Ladiwala Shiraz ShabanaliDirectorAug 15Option Exercise0.001,05501,460Aug 16 03:45 PM
Ladiwala Shiraz ShabanaliDirectorAug 15Option Exercise0.004001,500Sep 06 12:36 PM
Sullivan John JamesDirectorAug 15Option Exercise0.00754029,004Aug 16 03:37 PM
Alltoft Jennifer SadieDirectorAug 15Option Exercise0.0075402,400Aug 16 03:28 PM
Schmieder John BradleyDirectorAug 15Option Exercise0.00754069,760Aug 16 03:19 PM
Hall ShannonDirectorAug 15Option Exercise0.0075401,711Aug 16 02:03 PM
Owens Gary MPresident and CEOJun 16Option Exercise0.002,820030,992Jun 21 01:22 PM
Archbold Brian DavidSVP OperationsJun 16Option Exercise0.0061202,247Jun 21 12:23 PM
Sakys JohnCFOJun 16Option Exercise0.00848011,019Jun 21 12:02 PM
Sullivan John JamesDirectorJun 16Option Exercise0.0015028,256Jun 21 01:38 PM
Schmieder John BradleyDirectorJun 15Option Exercise0.0030069,006Jun 16 07:46 PM
Owens Gary MCEOJun 15Option Exercise0.002,823029,409Jun 16 07:37 PM
Archbold Brian DavidSVP OperationsJun 15Option Exercise0.0061401,918Jun 16 07:10 PM
Sakys JohnCFOJun 15Option Exercise0.00848010,544Jun 16 06:24 PM
Sullivan John JamesDirectorJun 15Option Exercise0.0015028,247Jun 16 07:56 PM
Sakys JohnCFOMar 24Option Exercise85.132,128181,14710,824Mar 27 09:40 AM
Sakys JohnCFOMar 24Sale167.012,128355,3979,696Mar 27 09:40 AM
Sakys JohnCFOMar 22Option Exercise122.662,500306,65012,196Mar 27 09:40 AM
Sakys JohnCFOMar 22Sale171.622,500429,0509,696Mar 27 09:40 AM
Sakys JohnCFOMar 15Option Exercise70.561,00070,56010,696Mar 16 02:42 PM
Sakys JohnCFOMar 15Sale165.711,000165,7109,696Mar 16 02:42 PM
Sakys JohnCFOMar 09Option Exercise70.5640028,22410,096Mar 09 06:13 PM
Sakys JohnCFOMar 09Sale169.9740067,9889,696Mar 09 06:13 PM
Sakys JohnCFOFeb 09Option Exercise51.851,00051,85010,696Feb 09 08:04 PM
Sakys JohnCFOFeb 09Sale184.271,000184,2709,696Feb 09 08:04 PM
Sakys JohnCFOJan 23Option Exercise70.562,100148,17611,796Jan 25 12:23 PM
Sakys JohnCFOJan 23Sale210.192,100441,3999,696Jan 25 12:23 PM
Schmieder John BradleyDirectorJan 13Sale191.311,571300,54868,976Jan 17 10:52 AM
Hall ShannonDirectorDec 08Sale174.9723040,244957Dec 09 09:00 AM
Schmieder John BradleyDirectorNov 11Sale175.452,500438,62568,976Nov 21 10:06 AM